Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months

Shilpa Medicare Unit IV, Jadcherla has cleared TGA, Australia GMP inspection

This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years

Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Merck and Eisai update on Two Phase 3 Trials Evaluating Keytruda plus Lenima for cell lung cancer

The companies will work with investigators to share the results with the scientific community

Parexel appoints Gwyn Bebb to lead oncology clinical development

Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need

Merck receives positive EU CHMP opinion for Keytruda as adjuvant treatment for cell lung cancer

Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial

Biocon Biologics completes integration of Viatris Biosimilars’ business in North America

Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris

Lincoln Pharmaceuticals posts Q1 FY24 standalone net profit at Rs. 19.01 Cr

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease